

INFORMATION ONLY

Introduction of Glassia

Customer Letter # 2023-31

2023-11-01

Dear Colleagues:

Canadian Blood Services is pleased to announce **Alpha-1 Proteinase Inhibitor [Human] Injection (Glassia)** will be listed with criteria on the Plasma Protein and Related Products Formulary for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI (A1-PI), also known as alpha1-antitrypsin deficiency (AATD).

Canadian Blood Services anticipates that Glassia will be available for hospital customers to order in early 2024. A subsequent Customer Letter with all outstanding details, including the link to the updated request and order form, will be released once a final date is confirmed.

Access to Glassia will be managed through Canadian Blood Services' Named Patient Contract process. Requests for Glassia can be submitted using the "Request for Patient Designated Plasma Protein and Related Products" form once it has been updated with the criteria. The form will specify that Glassia can be requested for adult patients with severe A1-PI deficiency and clinical evidence of emphysema who meet the following criteria*:

- Respiriologist has confirmed the diagnosis of severe A1-PI deficiency and clinical evidence of emphysema and indicated that patient would benefit from treatment with A1-PI product.
- A1-PI deficiency, defined as serum A1-PI levels <11 µM/L or < 80 mg/dL before start of the treatment, and
- Clinical evidence of emphysema (FEV1 <80%), and
- Patients must be nonsmokers for at least 6 months.
- For patients who have not received a lung transplant.

*Criteria is based on recommendations from CADTH

Key Product Highlights:

- Vial Size: 1000 mg/50 mL Vial
- Storage temperature: +2°C to +8°C
- Route of administration: Intravenous

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the “Hospital Services” section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,
Sylvain Grenier
Director, Plasma Protein and Related Products Formulary Program